Schedule 13G ownership disclosure
BIOXCEL THERAPEUTICS INC
Common Stock, par value $0.001 · CUSIP: 09075P105
Event date: 2025-12-31
- Filing-level shares
- 156,066.00
- Percent of class
- 0.6%
- Qatar Investment Authority
Shares: 156,066.00 · Class: 0.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001441449-26-000004
- Form type
- SCHEDULE 13G/A
- Filer
- BioXcel Therapeutics, Inc.
- CIK
- CIK 1720893
- Filed
- Mar 30, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership